Aims: Colistin became the critical treatment option for multidrug-resistant Gram-negative bacteria (GNB); however, resistance to colistin is increasingly being reported among clinical isolates. New therapy strategies should be considered nowadays. The aim of this study was to investigate the in vitro activity of a novel β-lactam/β-lactamases inhibitor ceftazidime-avibactam (CZA) alone and in combination with amikacin against colistin-resistant Gram-negative pathogens.

中文翻译：

---

头孢他啶-阿维巴坦单独和联合阿米卡星对粘菌素耐药革兰氏阴性病原体的体外活性

目的：粘菌素成为多重耐药革兰氏阴性菌（GNB）的关键治疗选择；然而，在临床分离株中越来越多地报道了对粘菌素的耐药性。现在应该考虑新的治疗策略。本研究的目的是研究一种新型 β-内酰胺/β-内酰胺酶抑制剂头孢他啶-阿维巴坦 (CZA) 单独和联合阿米卡星对粘菌素耐药革兰氏阴性病原体的体外活性。